INCREASED MORTALITY, CV, THROMBOEMBOLIC EVENTS, AND TUMOR PROGRESSION WITH THE ERYTHROCYTE STIMULATING AGENTS (ESAs) ARANESP, EPREX, RECORMON
2008-03-26
The U.S. equivalent of the Saudi Food and Drug Authority (SFDA) now requires significantly stronger warnings in the prescribing information for the erythrocyte stimulating agents (ESAs). The ESAs are used in to increase red blood cell production in patients with end stage renal disease and cancer patients. The ESA products approved for sale in Saudi Arabia are Aranesp, Eprex, and Recormon.